Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a treatment for relapsed and refractory multiple myeloma (RRMM).
Sanofi has hit back on a decision by NICE not to recommend NHS use of Sarclisa as part of a regimen for relapsed and refractory multiple myeloma (RRMM), claiming the agency would not consid
Over the last decade, treatments for the blood cancer myeloma have come on in leaps and bounds – but it remains incurable and unpredictable for individual patients and clinicians.<
Research-based charities are taking on an ever-growing role in frontline clinical research, and Myeloma UK has just launched a ‘stratified medicine’ trial aimed at helping high risk patient